Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4

Polonini, Hudson; Loures, da Silva Sharlene; Neves, Cunha Carolina; de, Oliveira Ferreira Anderson; Anagnostou, Korina; Dijkers, Eli

Abstract

Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4

Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli

Issue: May/Jun 2020 - Volume 24, Number 3

View All Articles in Issue

Page(s): 252-262

Download in electronic PDF format for $75

Abstract

To allow for tailored dosing and overcome swallowing difficulties, compounded liquid medication is often required in pediatric patients. The objective of this study was to evaluate the stability of oral suspensions compounded with SyrSpend SF PH4 and the commonly used active pharmaceutical ingredients azathioprine (powder) 50 mg/mL, azathioprine (from tablets) 50 mg/mL, clonidine hydrochloride (powder) 0.1 mg/mL, clopidogrel bisulfate (from tablets) 5 mg/mL, ethambutol hydrochloride (powder) 50 mg/mL, ethambutol hydrochloride (from tablets) 50 mg/mL, ethambutol hydrochloride (powder) 100 mg/mL, griseofulvin (powder) 25 mg/mL, hydralazine hydrochloride (powder) 4 mg/mL, nitrofurantoin (powder) 10 mg/mL, and thioguanine (powder) 2.5 mg/mL. Suspensions were compounded at the concentrations listed above and stored at controlled room and refrigerated temperatures. Stability was assessed by measuring the percentage recovery at 0 day (baseline), and at 7 days, 14 days, 30 days, 60 days, and 90 days. Active pharmaceutical ingredients quantification was performed by high-performance liquid chromatography, via a stability-indicating method. The following oral suspensions compounded using SyrSpend SF PH4 as the vehicle showed a beyond-use date of 90 days when stored both at room or refrigerated temperatures: clonidine hydrochloride 0.1 mg/mL, ethambutol hydrochloride 50 mg/mL and 100 mg/mL, griseofulvin 25 mg/mL, nitrofurantoin 10 mg/mL, and thioguanine 2.5 mg/mL, all compounded from the active pharmaceutical ingredients in powder form. Suspensions compounded using the active pharmaceutical ingredients from tablets presented a lower beyond-use date: 30 days for ethambutol hydrochloride 50 mg/mL and hydralazine hydrochloride 4 mg/mL, stored at both temperatures, and for clopidogrel bisulfate 5 mg/mL when stored only at refrigerated temperature. Azathioprine suspensions showed a beyond-use date of 14 days when compounded using active pharmaceutical ingredients in powder form at both temperatures. This suggests that SyrSpend SF PH4 is suitable for compounding active pharmaceutical ingredients from different pharmacological classes.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2020 Pg. 252-262	Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
Jan/Feb 2002 Pg. 66-69	Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes Author(s): Xu Quanyun A, Trissel Lawrence A, Pham Lien
Nov/Dec 2018 Pg. 516-526	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
May/Jun 2016 Pg. 231	Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm Author(s): Allen Loyd V Jr
Mar/Apr 2024 Pg. 135	Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 493	Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2017 Pg. 255-263	Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions Author(s): de Oliveira Ferreira Anderson, Polonini Hudson C, Loures da Silva Sharlene, Cerqueira de Melo Victor Augusto, de Andrade Laura, Fernandes Brandão Marcos Antônio
Jan/Feb 2020 Pg. 60	Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2016 Pg. 426-434	Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions Author(s): Polonini Hudson C, Loures Sharlene, de Araujo Edson Peter, Brandão Marcos Antônio F, Ferreira Anderson O
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Mar/Apr 2020 Pg. 134	Nitrofurantoin 2 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Jul/Aug 2023 Pg. 330-339	Physiochemical and Microbiological Stability of Azathioprine Suspensions in PCCA Base, SuspendIt Author(s): Pramar Yahoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Jan/Feb 2021 Pg. 44	Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2018 Pg. 146	Clonidine Hydrochloride 10 mg/mL in Inorpha Solution Author(s): Allen Loyd V Jr
Jan/Feb 2005 Pg. 66	Lidocaine Hydrochloride-2%, Ketolorac Tromethamine-3%, and Clonidine Hydrochloride-0.1% Injection Author(s): Allen Loyd V Jr
Jan/Feb 2007 Pg. 71	Clonidine Hydrochloride 0.1-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 418	Imipramine Hydrochloride 5-mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 505	Pyridoxine Hydrochloride 25 mg/mL in Oral Mix and Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2022 Pg. 149	Pyridoxine Hydrochloride 50 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Jul/Aug 2024 Pg. 334-343	Physicochemical and Microbiological Stability of Compounded Clonidine Hydrochloride Oral Liquid Dosage Forms in PCCA Base, SuspendIt® Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Johnson Jyra, Graves Richard A